Shuttle Pharmaceuticals (SHPH) announced the filing of a provisional patent application with the United States Patent and Trademark Office entitled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.” The filing is yet another critical advancement within the company’s Diagnostic subsidiary which aims to develop highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, leveraging its high expression on prostate cancer cells for accurate imaging and for targeted therapy delivery using radio labelled PSMA ligands. The filing comes through Shuttle Pharma’s collaboration with Alan Kozikowski.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHPH:
- Shuttle Pharmaceuticals Appoints New Interim CEO and CSO
- Shuttle Pharma Secures $5.2M in Public Offering
- Shuttle Pharmaceuticals prices 19.17M shares at 30c per share in public offering
- Shuttle Pharmaceuticals Appoints Christopher Cooper as Co-CEO
- Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO